Search

Reading Time: 3 minutesThe field of in-silico clinical trials is at the forefront of industry innovation. And advancements in this area—from computational modeling and simulation to generative AI and synthetic data—have the potential to drastically impact medical device development. Steve Levine, Sr. Director of Human Modeling at Dassault Systèmes and Afrah Shafquat, Sr. Data Scientist II at Medidata […]

Article

Reading Time: 3 minutesThe 42nd annual J.P. Morgan Healthcare Conference (JPM) showcased Medidata’s groundbreaking work in artificial intelligence (AI)—a central theme that emerged during the three-day gathering in San Francisco. From investors and large biopharma and contract research organizations, to early-stage biotechs, attendees were focused on AI’s transformative potential in drug discovery and clinical trial design and how […]

Article

Reading Time: 4 minutesThis blog was authored by Matt Noble, SVP, Product Management, Patient Cloud at Medidata. As the clinical trial landscape evolves, efficient and effective patient data collection is critical in understanding the impact of novel treatments. Today’s clinical research professionals are looking to increase efficiency. At the same time, the complexity of clinical trials has increased […]

Article

Reading Time: 6 minutesThis blog was authored by Christopher Tyers, Client Services Principal at Medidata. At November’s Medidata NEXT New York 2023, 500+ clinical trial sponsors and partners came together with a focus on the betterment of complex clinical trials. The synergy of their collective experience, expertise, thought leadership, and shared insights led to industry-shaping discussions and a […]

Article

Reading Time: 4 minutesIn the rapidly evolving landscape of artificial intelligence (AI), its integration across various sectors is undeniable—with healthcare and drug development at the forefront of this transformation. Explore how this technology is revolutionizing the life sciences industry in this conversation between Medidata’s Afrah Shafquat, Senior Data Scientist II and Jacob Aptekar, VP, Trial Design Solutions, Medidata […]

Article

Reading Time: 3 minutesGenerative AI continues to rapidly become a global buzzword, and we’re seeing more industries quickly adopt this technology. But for many, a lack of understanding the capabilities and nuances of gen AI have hindered adoption—despite its enormous potential. The healthcare and life sciences industry is one area where generative AI is poised to make the […]

Article

Reading Time: 5 minutesIf artificial intelligence (AI) and clinical trials have been on your mind, this is a must-watch session. Andrea Falkoff, Senior Director, Product Management at Medidata moderated a panel discussion at Medidata NEXT New York 2023 with thought leaders from RadMD, BIOVIA, and AstraZeneca, discussing innovation in AI—the much-debated technology. The group shared insights into AI’s […]

Article

Reading Time: 4 minutesUnsurprisingly, clinical trial financial management (CTFM) is complex. Surprisingly, a proper end-to-end CTFM solution does not exist... yet. At Medidata NEXT New York 2023, Meghan Harrington, VP, Clinical Trial Financial Management, outlined why an actual end-to-end financial process is needed and shared an exciting announcement. CTFM Complexity in Context While the focus of any […]

Article

Reading Time: 3 minutesThe transformative power of collaboration is no better illustrated than in life sciences. By sharing vital data, insights, and discoveries, we can power leaps and bounds in healthcare that improve and save lives every day. The life sciences industry is at an inflection point. The transformative power of artificial intelligence (AI) and machine learning to […]

Article

Reading Time: 3 minutesThe use of generative (gen) AI in clinical trials has the potential to decrease the generally lengthy timelines and high costs (Boston Consulting Group, 2023). While it’s been a challenge to gain a full understanding of the implications and capabilities of gen AI—especially in the healthcare and life sciences industry—one promising area is in protocol […]

Article

Reading Time: 3 minutes Only 10 percent of new drugs that complete the first phase of a clinical trial make it to market, and by Phase III, patient participation drops by over 30 percent. Bogged down by regulatory glitches, logistical difficulties, and other problems, traditional clinical trials often fail—and that means new drugs, devices, and other treatments can take […]

Article

Reading Time: 3 minutesThis blog was authored by Paul O’Donohoe, Senior Director, eCOA Product and Science at Medidata. As we continue to innovate and evolve in the clinical trials space, the spotlight has rightfully shone on improving the patient experience. The emphasis placed on patient centricity is crucial, aiming to minimize burden and enhance the overall journey for […]

Article